Login / Signup

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

M A PowellL BjørgeL WillmottZ NovákD BlackL GilbertS SharmaG ValabregaL M LandrumM Gropp-MeierA StuckeyI BoereM A GoldY SegevS E GillC GennigensA SebastianelliM S ShahinB PothuriB J MonkJ BuscemaR L ColemanB M SlomovitzK L RingT J HerzogM M BalasM GrimshawS StevensD W LaiC McCourtM R Mirza
Published in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
Dostarlimab in combination with carboplatin-paclitaxel demonstrated a statistically significant and clinically meaningful OS benefit in the overall population of patients with primary advanced or recurrent EC while demonstrating an acceptable safety profile.
Keyphrases
  • phase iii
  • endometrial cancer
  • open label
  • double blind
  • clinical trial
  • phase ii
  • placebo controlled
  • phase ii study
  • study protocol
  • chemotherapy induced
  • randomized controlled trial
  • radiation therapy
  • newly diagnosed